Skip to main content

Find Clinical Trials

Home
Conditions
EGFR Activating Mutation

Clinical trial condition

EGFR Activating Mutation

Explore clinical trials studying EGFR Activating Mutation. Study availability and eligibility vary by location and protocol.

20 public trials 8 recruiting studies

Refine in advanced search Browse all conditions

EGFR Activating Mutation trial results

Recruiting

TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

NCT05948813

Conditions: Brain Diseases, Brain Metastases, Brain Neoplasms, +8 more
Locations: National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College Beijing, Beijing Municipality, China

View Trial Details

Recruiting

EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC

NCT07637448

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +10 more
Locations: Southern Medical University Nanfang Hospital Department of Oncology Guangzhou, Guangdong, China

View Trial Details

Recruiting

Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis

NCT07348965

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +16 more
Locations: Guangdong Provincial Hospital of Chinese Medicine Guangzhou, Guangdong, China

View Trial Details

Recruiting

CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease

NCT05257967

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +15 more
Locations: BC Cancer Vancouver, British Columbia, Canada

View Trial Details

Recruiting

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

NCT06363734

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +11 more
Locations: Department of Thoracic Medical Oncology, Tianjin Medical University Cancer Hospital Tianjin, Tianjin Municipality, China

View Trial Details

Recruiting

A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)

NCT06053099

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +11 more
Locations: Angers - CHU Angers, France

Bayonne - CH Bayonne, France

Boulogne - Ambroise Paré Boulogne, France

Lyon - URCOT Bron, France

View all 36 locations

View Trial Details

Recruiting

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

NCT05382728

Conditions: EGFR Activating Mutation, NSCLC
Locations: Hunan Provincial Tumor Hospital Changsha, Hunan, China

Shanghai Chest Hospital Shanghai, Shanghai Municipality, China

View Trial Details

Recruiting

Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases

NCT05768490

Conditions: Brain Diseases, Brain Metastases, Brain Neoplasms, +8 more
Locations: Sun-Yat-Sen university Guangdong, Guangzhou, China

View Trial Details

Not yet recruiting

First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) Alterations

NCT07699952

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +10 more
Locations: Not specified

View Trial Details

Not yet recruiting

Comparative ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET/CT Imaging for Assessing TROP2 ADC Therapeutic Efficacy in EGFR-TKI Resistant Advanced NSCLC

NCT07685197

Conditions: EGFR Activating Mutation, EGFR-TKI-resistant Non-Small Cell Lung Cancer, NSCLC, +2 more
Locations: Not specified

View Trial Details